Phaseline

Targets › HADH

HADH (Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Other; next expected readout Dec 2026.

Mitochondrial fatty acid beta-oxidation enzyme that catalyzes the third step of the beta-oxidation cycle for medium and short-chain 3-hydroxy fatty acyl-CoAs (C4 to C10). Plays a role in the control of insulin secretion by inhibiting the activation of glutamate dehydrogenase 1 (GLUD1), an enzyme that has an important role in regulating amino acid-induced insulin secretion (By similarity). (UniProt, Q16836)

Open in Phaseline: the race on HADH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ain Shams UniversityTrimetazidine
3-ketoacyl-CoA thiolase inhibitor; shifts cardiac energy metabolism from fatty acid oxidat
HADHPhase 3Aluminum Phosphide PoisoningDec 2026

Conditions

Aluminum Phosphide Poisoning (1)

Modalities

small molecule (1)

Companies

Ain Shams University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.